ABSTRACT 6-min walk distance (6MWD) has recently been shown to be associated with the risk of mortality in patients with idiopathic pulmonary fibrosis (IPF); however, the independent contribution of 6MWD to the prediction of mortality risk has not been evaluated in a large, well-defined population of patients with IPF.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal fibrotic lung disease characterised by progressive pulmonary insufficiency and diminished exercise capacity [1] . Periods of transient clinical stability may occur; however, continued disease progression is inevitable [2] . The prognosis is poor, with an estimated 5-year survival rate that is comparable to several neoplastic disorders, including cancers of the lung, liver and brain [3, 4] .
Several studies have identified independent predictors of mortality in patients with IPF, including age, respiratory hospitalisation, forced vital capacity (FVC) % predicted, and longitudinal change in FVC % pred [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . The 6-min walk distance (6MWD), a practical and widely used measure of clinical status in patients with a variety of cardiopulmonary diseases [17] [18] [19] [20] [21] [22] , has recently been shown to be associated with the risk of mortality in patients with IPF [23] [24] [25] ; however, the independent contribution of 6MWD to the risk of mortality has not been formally evaluated in a large, well-defined population of patients with IPF.
We previously reported the test performance characteristics of the 6-min walk test (6MWT) in patients with IPF [23] . A novel finding of our study was the observation that 6MWD and 24-week change in 6MWD were highly predictive of 1-year mortality despite relatively weak correlations between 6MWD and various measures of pulmonary function known to be independent predictors of mortality. Based on this observation, we hypothesised that the 6MWT might interrogate a separate domain of the disease process and provide incrementally informative data regarding the prognosis of patients with IPF. The aim of the present study, therefore, was as follows. 1) To evaluate the contribution of 6MWD to the prediction of risk of all-cause mortality in patients with IPF, independent of other indices we have previously reported to predict mortality; and 2) to assess the change in model performance when 6MWD is added to the previously published clinical model [7] .
Methods

Source and study populations
The source population included all randomised patients in a prospective, double-blind, placebo-controlled phase 3 trial evaluating treatment with interferon c-1b in patients with IPF (GIPF-007 (INSPIRE) trial; n5826) [26] . From the source population, we selected for inclusion all patients who completed a baseline and week 24 study visit (n5748); patients who died (n520) or had a lung transplant (n51) between baseline and week 24 were thus excluded from the analysis. Clinical efficacy outcomes in the original trial revealed no evidence of a treatment effect; therefore, the analysis included data from both treatment groups to maximise study power [26] .
Criteria for enrolment in the original trial have been previously described [26] . Briefly, eligible patients had a confident IPF diagnosis according to the criteria of the American Thoracic Society/European Respiratory Society [27, 28] , FVC o55% of the predicted value, diffusing capacity of the lung for carbon monoxide (DLCO) o35% of predicted, either FVC or DLCO f90% of predicted, and a 6MWT distance o150 m. Patients with a history of unstable or deteriorating cardiac, vascular or neurological disease within the previous 6 months and patients on a waiting list for lung transplantation at the time of randomisation were excluded from enrolment.
Study protocol
Eligible patients underwent a complete physical examination and assessments of physiological function (FVC, DLCO and resting alveolar-arterial gradient), dyspnoea (according to the University of California San Diego Shortness of Breath Questionnaire), health-related quality of life (according to St George's Respiratory Questionnaire) and exercise capacity (6MWT) at the baseline study visit and at 24-week intervals thereafter.
The 6MWT was performed indoors on a flat, straight corridor with a hard surface. An oxygen titration procedure was performed at the screening visit to establish a baseline flow rate for patients who required supplemental oxygen; all subsequent tests during the study period were performed using the baseline oxygen flow rate established during the titration procedure. Before each 6MWT, patients were required to have resting oxygen saturation as measured by pulse oximetry of at least 83% after 10 min of rest breathing room air or at the baseline O 2 flow rate. Patients were instructed to walk as far as they could without jogging or running; if they needed to slow down or stop to rest they were permitted to do so and encouraged to resume walking as soon as they were able. The test was stopped if the patient experienced chest pain, intolerable dyspnoea, leg cramps, diaphoresis or desaturation below 83%.
Two observation periods were used to maximise the number of events and enhance the power of the study to detect significant relationships between predictor variables and 1-year mortality. Predictors of mortality were assessed during the period from the trial baseline to the week 24 trial visit, and during the period from the week 48 to the week 72 trial visits, respectively. These periods served as the ''run-in'' phases during which changes in longitudinal predictors of mortality were measured; all deaths occurring over the subsequent 48-week periods were identified and flagged accordingly ( fig. 1 ). All data from the two periods were pooled into a single dataset for analysis; therefore, patients may have contributed up to two unique observations to the study database.
Statistical analysis
A multivariate Cox proportional hazards model was used to characterise the relationship between risk factors of interest and all-cause mortality. Risk factors of interest included the independent predictors of mortality in the previously published clinical model (age, respiratory hospitalisation, FVC % pred and 24-week change in FVC % pred) [7] , as well as 6MWD and 24-week change in 6MWD. Categorical thresholds were retained for risk factors of interest from the original clinical model; categorical thresholds for baseline 6MWD and 24-week change in 6MWD were selected based on prior research [23] .
The presence of multicollinearity, hazards assumptions and model discrimination were evaluated using published methods [29, 30] . Model discrimination was quantified based on the C-statistic and compared against the previously published clinical model. The C-statistic is a measure of the probability that among two randomly selected patients the patient with the higher predicted risk of an event will be the first to experience the event. Values range from 0.5 (model discrimination is no better than chance) to 1.0 (perfect discrimination). Values between 0.70 and 0.80 were assumed to signify ''acceptable'' model discrimination; values exceeding 0.80 were assumed to represent ''excellent'' discrimination. Model performance was also evaluated by calculating the net reclassification improvement (NRI) for the model including 6MWD and change in 6MWD compared with the original model (based on patients in study GIPF-007). The NRI can be quantified as a sum of differences in proportions of individuals moving up in risk categories minus the proportion moving down for subjects who develop events, and the proportion of individuals moving down minus the proportion moving up for people who do not develop events [30] .
Results
A total of 748 patients completed a week 24 study visit in the original clinical trial and therefore qualified for inclusion in the study population. Demographics and baseline characteristics are summarised in table 1. The mean¡SD age at study entry was 66¡7.6 years and 71.5% of patients were male. Mean values for FVC % pred and DLCO % pred were 72.5¡12.8 and 47.5¡9.2, respectively. The mean¡SD distance walked during the 6MWT was 397¡107 m. A total of 86 (11.5%) patients required supplemental oxygen during the 6MWT; among these, the mean baseline oxygen flow rate was 2.84 L?min
There was a total of 79 deaths during the two periods of observation (n (patient visits)51156; see online supplementary table E1); 59 deaths occurred between the week 24 and week 72 study visits (mean duration The unadjusted risk of 1-year all-cause mortality and Kaplan-Meier survival distributions by baseline 6MWD and 24-week change in 6MWD are summarised in table 2 and figure 2, respectively. In the unadjusted analyses, both baseline 6MWD and 24-week change in 6MWD were associated with the risk of 1-year mortality. Patients with a .50 m decline in 6MWD at 24 weeks (versus f25 m decline) had the largest relative risk (hazard ratio (HR) 3.76, 95% CI 2.26-6.27; p,0.001).
In the multivariate analysis, all risk factors of interest were found to be statistically significant independent predictors of all-cause mortality, including age, respiratory hospitalisation, FVC % pred, 6MWD and 24-week changes in FVC % pred and 6MWD (table 3) . Baseline 6MWD ,250 m was independently associated with a two-fold increase in the risk of 1-year mortality (HR 2.12, 95% CI 1.15-3.92; p50.02) and a 24-week decrement in 6MWD .50 m was independently associated with a nearly three-fold increase in the risk of mortality at 1 year (HR 2.73, 95% CI 1.60-4.66; p,0.01). Additionally, inclusion of 6MWD and 24-week change in 6MWD improved model discrimination compared with the original clinical model As the original clinical model included a subset of 330 patients from the GIPF-001 study for whom 6MWT data were not collected, a multivariate analysis using the predictor variables in the original clinical model was repeated in the subset of patients (n5748) 
Discussion
The hallmark clinical features of IPF include progressive pulmonary insufficiency and reduced exercise capacity. While declines in lung function and exercise capacity are inevitable, considerable variability may be observed in the rate of disease progression, both within and between patients. Moreover, longitudinal changes in the various measures used to assess clinical status in patients with IPF are only weakly correlated; periods of transient stability in one measure may coincide with marked declines in others [23, 31] . As a result of the highly variable and enigmatic clinical course, formulating an accurate prognosis in the individual patient represents a distinct challenge for clinicians. The identification of accurate predictors of mortality that are readily and reliably ascertainable in the typical clinical setting, therefore, has obvious and important implications for the clinical management of patients with IPF.
We previously reported that a simplified clinical risk prediction model comprised of four predictors that are widely accessible in the clinical setting accurately predicts near-term mortality in patients with IPF [7] . The predictors included age, history of respiratory hospitalisation within the preceding 24 weeks, FVC % pred and 24-week change in FVC % pred. In the present study, we further demonstrate that 6MWD and 24-week change in 6MWD are independent predictors of near-term mortality in patients with IPF and that a novel clinical risk prediction model comprised of age, respiratory hospitalisation, FVC % pred, 6MWD and 24-week changes in FVC % pred and 6MWD improves the ability to discriminate between patients on the basis of risk compared with the previously published clinical model.
The 6MWT has several potential advantages as a measure of clinical status in patients with IPF. The test is practical, inexpensive and reliable; it requires no special equipment or advanced training and can be performed by all but the most severely impaired patients [32] . Additionally, 6MWD is highly reproducible in patients with IPF [23, 33] and changes in 6MWD have been shown to correlate with changes in measures of physiological function and health-related quality of life [23] . As the 6MWT is self-paced, it is both better tolerated and more reflective of activities of daily living than other walk tests [34] . Finally, the 6MWT may be incrementally informative in the assessment of disease progression in IPF patients with comorbid emphysema by capturing functional deficits that would otherwise be masked due to the spurious preservation of FVC [33] .
Only two previous studies have demonstrated an independent association between 6MWD and the risk of mortality in patients with IPF [24, 25] . In a retrospective review of data from 44 patients with IPF, 29 of whom had an additional evaluation at 12 months, CAMINATI et al. [24] reported that both baseline 6MWD (,212 m) and change in 6MWD at 12 months were independently associated with an increased risk of mortality. The study was limited by the modest sample size and the retrospective nature of the analysis, as well as the exclusion of patients who were unable to perform the 6MWT without the use of supplemental oxygen. However, the findings were generally consistent with a previous study by LEDERER et al. [25] that evaluated the prognostic utility of 6MWD in 454 patients with IPF who were on a waiting list for lung transplantation. In this study, baseline 6MWD (,207 m) was strongly and independently associated with an increased risk of mortality at 6 months and performed better than baseline FVC % pred as a predictor of waiting list survival. It is of note that longitudinal change in 6MWD was not evaluated as a potential predictor of mortality, and the 6MWT was not performed according to a standardised protocol across study sites. Moreover, patients listed for lung transplantation represent a distinct cohort; on average, patients in this study were younger and had more severe physiological impairment and a higher prevalence of comorbid pulmonary hypertension than IPF patients who are not candidates for lung transplantation. As a result, the degree to which the findings can be generalised to the broader population of patients with IPF is unknown.
In the present analysis, we examined the specific contribution of 6MWD to the risk of near-term mortality in a large and well-defined population of patients with a confident diagnosis of IPF and broad range of impairment in physiological measures of disease status. Baseline 6MWD ,250 m was independently associated with a two-fold increase in the risk of 1-year mortality, and a 50 m decrement in 6MWD at 24 weeks conferred a nearly three-fold increase in the risk of mortality during the subsequent year, even after controlling for age, respiratory hospitalisation, FVC % pred and 24-week change in FVC. This latter finding is particularly noteworthy, as it establishes for the first time in a large, multinational study that longitudinal change in 6MWD is strongly and independently associated with the risk of near-term mortality in patients with IPF. While our results also demonstrated a significant relationship between a 24-week decrement in 6MWD of 26-50 m and the risk of 1-year mortality, we chose to focus on the threshold of a 50 m decrement based on prior work in which the minimal clinically important difference for the 6MWT was estimated as 24-45 m [23] . We selected the higher threshold because we did not wish to sacrifice specificity in order to improve sensitivity.
A further noteworthy finding of this study is the observation that the addition of 6MWD to a parsimonious clinical model based on four widely available and inexpensive measures of disease status provides data that is incrementally informative in the prognostic evaluation of individual patients with IPF. Model discrimination, as measured by the C-statistic, improved from 0.75 (95% CI 0.71-0.81) to 0.80 (95% CI 0.76-0.85) when 6MWD and 24-week change in 6MWD were added to a model comprised of age, respiratory hospitalisation, FVC % pred and 24-week change in FVC % pred. The magnitude of improvement in model discrimination is notable, as large independent associations with the dependent variable are required for the addition of a predictive marker to result in a meaningful increase in the Cstatistic [29] . For example, PENCINA et al. [29] evaluated the improvement in model performance by the introduction of high-density lipoprotein (HDL) cholesterol into a standard prediction model for a first coronary heart disease (CHD) event in 3264 subjects who were part of the Framingham Heart Study. HDL cholesterol was independently associated with the risk of a CHD event (HR 0.64; p,0.001); however, the addition of HDL cholesterol to a standard model comprised of age, sex, smoking status and systolic blood pressure had a negligible effect on model discrimination (C-statistic 0.77 versus 0.76; p5nonsignificant). In The findings of our study should be interpreted in the context of several important limitations. First, source data for our analysis was obtained from a clinical trial that enrolled patients with mild-to-moderate impairment in baseline measures of lung function and exercise capacity. Patients with severe functional impairment or those with selected comorbidities including severe emphysema and unstable cardiovascular disease were excluded from enrolment. While the study population probably included patients with mildto-moderate emphysema, as well as patients who developed severe impairment in physiological function during the interval preceding the second observation period (week 72 to week 120), the degree to which our findings can be generalised to these populations is uncertain.
Secondly, risk factors of interest and the corresponding categorical thresholds in our model were identified a priori based on prior research. Since the primary aims of the study were to assess the independent contribution of 6MWD to the risk of mortality and evaluate the predictive value of 6MWD when added to the previously published clinical prediction model, no formal model specification procedures were undertaken in the primary analysis to specify the model de novo. Thirdly, as noted in our prior publication [7] , hospitalisations were designated as respiratory in nature based on the clinical judgment of the primary investigator and were not formally adjudicated. We note, however, that our original intent was to develop a risk prediction model that could be used in the clinical setting to quickly and accurately formulate a prognosis based on readily available data. Accordingly, we believe that the manner in which hospitalisations were characterised is more reflective of typical clinical practice, thereby potentially enhancing the clinical utility of the model. Finally, the 6MWT was performed with strict adherence to a standardised protocol following a formal oxygen titration procedure; the replication of such rigorous methods in the typical clinical setting, while possible, cannot be assured. Indeed, our decision not to develop a revised risk scoring system was based largely on the probable inconsistent clinical application of standardised procedures for the 6MWT. Nonetheless, we believe that the strength of the relationship between 6MWD and the risk of mortality warrants consideration in the clinical assessment of patients with IPF and has important implications for the design and execution of clinical trials.
In conclusion, the findings of the present study demonstrate that both 6MWD and longitudinal change in 6MWD are strong independent predictors of mortality in patients with IPF. Additionally, a clinical risk prediction model comprised of age, respiratory hospitalisation, FVC % pred, 6MWD and 24-week changes in FVC % pred and 6MWD reliably predicts 1-year mortality in patients with IPF and may be used to further refine the prognosis of individual patients and guide clinical decision making. Further research is warranted to validate the model in other large and independent patient populations.
